Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Department of Reproductive Endocrine and Infertility Medicine, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.
Eur J Obstet Gynecol Reprod Biol. 2024 Oct;301:1-11. doi: 10.1016/j.ejogrb.2024.07.054. Epub 2024 Jul 27.
To conduct the first-ever systematic review and meta-analysis evaluating calcium infusion versus cabergoline in preventing ovarian hyperstimulation syndrome (OHSS) among high-risk women undergoing assisted reproductive technology.
Six databases were screened from inception until April 1, 2024. The included randomized and non-randomized controlled studies were assessed for quality. The endpoints included the severity of OHSS and selected pregnancy-related outcomes. Endpoints were summarized as risk ratios (RRs) and 95% confidence intervals (CIs) in a random-effects model.
Six studies were analyzed, including 1687 patients (828 in the calcium group and 859 in the cabergoline group). The quality of the studies varied and reflected low risk and high risk of bias in two and four studies, respectively, according to the revised Cochrane risk of bias tool. No significant differences were noted between both groups regarding the rates of overall (n = 5, RR = 0.65, 95 % CI [0.39, 1.07], p = 0.09), mild (n = 4, RR = 1.05, 95 % CI [0.59, 1.89], p = 0.86), moderate (n = 5, RR = 0.41, 95 % CI [0.15, 1.08], p = 0.07), and severe (n = 6, RR = 0.36, 95 % CI [0.11, 1.22], p = 0.1) cases of OHSS. Leave-one-out sensitivity analysis of an outlier study revealed that calcium significantly reduced the occurrence of severe OHSS compared with cabergoline (n = 5, RR = 0.16, 95 % CI [0.09, 0.43], p < 0.001, Higgins I = 0 %). No significant differences were observed between both groups regarding the rates of clinical pregnancy (n = 4, RR = 0.97, 95 % CI [0.88, 1.07], p = 0.57), ongoing pregnancy, live birth, and spontaneous abortion (Higgins I < 50 % for all).
Both agents yielded similar pregnancy-related outcomes. However, calcium infusion could potentially be more effective than cabergoline in reducing the rate of severe OHSS. Additional high-quality and well-controlled trials are essential to draw firm conclusions.
首次进行系统评价和荟萃分析,评估钙输注与卡麦角林预防接受辅助生殖技术的高危女性发生卵巢过度刺激综合征(OHSS)的效果。
从创建至 2024 年 4 月 1 日,筛选了 6 个数据库。对纳入的随机和非随机对照研究进行了质量评估。终点包括 OHSS 的严重程度和选定的妊娠相关结局。采用随机效应模型汇总风险比(RR)和 95%置信区间(CI)。
共分析了 6 项研究,包括 1687 名患者(钙组 828 名,卡麦角林组 859 名)。根据修订后的 Cochrane 偏倚风险工具,研究质量存在差异,其中两项研究的偏倚风险为低风险,四项研究的偏倚风险为高风险。两组患者的总体(n=5,RR=0.65,95%CI[0.39,1.07],p=0.09)、轻度(n=4,RR=1.05,95%CI[0.59,1.89],p=0.86)、中度(n=5,RR=0.41,95%CI[0.15,1.08],p=0.07)和重度(n=6,RR=0.36,95%CI[0.11,1.22],p=0.1)OHSS 发生率无显著差异。对一项异常值研究进行的逐一剔除敏感性分析显示,与卡麦角林相比,钙显著降低了重度 OHSS 的发生(n=5,RR=0.16,95%CI[0.09,0.43],p<0.001,Higgins I=0%)。两组患者的临床妊娠率(n=4,RR=0.97,95%CI[0.88,1.07],p=0.57)、持续妊娠率、活产率和自然流产率(Higgins I<50%)无显著差异。
两种药物均产生了相似的妊娠相关结局。然而,钙输注在降低重度 OHSS 发生率方面可能比卡麦角林更有效。需要更多高质量和良好对照的试验来得出确定的结论。